STOCKS TELEGRAPH

Tag: Sunshine Biopharma Inc

  • Sunshine Biopharma (SBFM) Stock Soars In Pre-Market Trading

    Sunshine Biopharma (SBFM) Stock Soars In Pre-Market Trading

    Sunshine Biopharma, Inc. (NASDAQ: SBFM) stock saw a sharp increase after the release of its 2024 financial report. SBFM shares rose 55.50% to $3.25 as of the most recent pre-market check. On Tuesday, April 1, 2025, the company formally submitted its annual report on Form 10-K, demonstrating remarkable financial expansion.

    Initiatives for Sales Growth and Expansion

    In 2024, Sunshine Biopharma reported a significant growth in sales, reaching $34.9 million, a noteworthy 45% increase over $24.1 million in the prior year. In order to finance the growth of its sales activities, SBFM also successfully concluded an underwritten public offering, raising about $10 million in gross revenues.

    Sunshine Biopharma introduced 13 new generic prescription medications in the last year, greatly expanding its pharmaceutical offering. Nine of these were disseminated through strategic partnerships, while four were introduced under cross-licensing agreements. Additionally, Health Canada granted SBFM regulatory authority to sell NIOPEG, a NEULASTA biosimilar, enhancing its portfolio of cancer medications.

    Breakthrough Therapeutics Research

    With its discoveries published in the Journal of Medicinal Chemistry, Sunshine Biopharma also achieved significant strides in therapeutic development. In a mouse model of SARS-CoV-2 infection, the study demonstrated the sub-micromolar potency and great in vivo efficiency of Sunshine Biopharma’s new coronavirus PLpro inhibitor,

    That highlighted its exceptional efficacy and was an important milestone in the company’s continuous attempts to create novel treatments for serious illnesses is this peer-reviewed study.

    Furthermore, Sunshine Biopharma’s K1.1 mRNA Lipid Nanoparticle showed potential as a new therapeutic agent for human hepatocellular carcinoma after completing proof-of-concept animal model studies. As the third most common cause of cancer-related fatalities globally, this kind of liver cancer continues to be a serious global health problem.

    Prospects for the Future and Strategic Development

    Sunshine Biopharma is unwavering in its desire to turn a profit and further its in-house medication research initiatives. As it works to introduce new life-saving medications to the market, SBFM expects to see further growth prospects in 2025 and beyond.

  • Is This Why The SBFM Stock Rose Last Trading?

    The stock of Sunshine Biopharma Inc [OTCPK: SBFM] soared 142.00% to $0.2420 at the previous close. Volume in Sunshine Biopharma stock was 96.69M shares compared with 7.46M shares over the past 30 days. SBFM stock value fluctuated between $0.0015 and $0.3000 during the last 52 weeks. SBFM stock climbed following announcing method of actions for its anti-cancer drug candidate.

    How did that method work?

    Sunshine Biopharma focuses on researching, developing, and commercializing antiviral and oncology drugs. Currently, SBFM is developing an oral treatment for COVID-19 in the area of antiviral drugs. There is no drug that can stop the replication of the virus in sufferers.

    Yesterday, Sunshine Biopharma announced that Adva-27a, the Company’s flagship anticancer drug candidate, had been elucidated for the first time.

    SBFM’s Adva-27a inhibits two cellular processes of P-glycoprotein evasion and Topoisomerase II inhibition. Over 50% of all cancer types increase multidrug resistance by secreting P-glycoprotein.

    Due to the fact that SBFM candidate Adva-27a escapes the efflux pump of P-glycoprotein, it accumulates inside cancer cells and destroys them by inhibiting Topoisomerase II, an enzyme that is frequently employed by cancer cells for multiplication.

    Scope of SBFM’s new drug:

    Adva-27a is able to destroy both populations of cancer cells, rendering cancer treatment more successful. SBFM’s this development could have a huge impact on cancer treatment in general. In the near future, Sunshine Biopharma (SBFM) is likely to offer a new drug to cancer sufferers worldwide.